We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study.
- Authors
Pederson, Holly J; Faubion, Stephanie S; Pruthi, Sandhya; Goldfarb, Shari
- Abstract
Additionally, 37% of the study population received no estrogen treatment (ET), which is inconsistent with current practice for hormone receptor-positive breast cancer and increases risk of recurrence. We express concern over the conclusion drawn based on this retrospective study of breast cancer (BC) patients treated from 1997 to 2004 that those on aromatase inhibitor (AI) therapy who use vaginal estrogen treatment (VET) have higher recurrence rates, especially because this was not seen in women receiving systemic menopausal hormone therapy (MHT) ([1]). Large prospective studies are needed using current BC risk stratification and treatments, monitoring of adherence, and use of newer lower-dose vaginal estrogen formulations.
- Subjects
HORMONE therapy; HORMONE receptor positive breast cancer; BREAST cancer; COHORT analysis; HER2 positive breast cancer; SCIENTIFIC observation
- Publication
JNCI: Journal of the National Cancer Institute, 2023, Vol 115, Issue 2, p220
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djac211